'Alexandra' General Hospital of Athens
Welcome,         Profile    Billing    Logout  
 10 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dimopoulos, Meletios A
NCT01788020 / 2013-000506-37: Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

Completed
3
202
Europe
Dexamethasone, Rituximab, Cyclophosphamide, Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
University of Ulm, Centre Hospitalier de Lens (Co-Sponsor)
Waldenström's Macroglobulinemia
11/18
04/24
Neptuno, NCT04784559 / 2020-005951-19: Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

Terminated
3
205
Europe, RoW
Plitidepsin, Dexamethasone, Remdesivir, Favipiravir
PharmaMar
COVID-19 Infection
03/23
03/23
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Calendar Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial)
Calendar Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Calendar Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jul 2023 - Dec 2023: Data readout from DREAMM-8 trial in combination with pomalidomide and dexamethasone for 2L+ multiple myeloma
Jul 2023 - Dec 2023: Acceptance of regulatory submission in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
More
Recruiting
3
357
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
05/29
DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruiting
2
177
Europe, Canada, US, RoW
Belantamab mafodotin
GlaxoSmithKline
Multiple Myeloma
08/24
02/25
NCT04263480: Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia

Recruiting
2
99
Europe
Carfilzomib + Ibrutinib, Ibrutinib
Christian Buske, Amgen, Janssen, LP
Waldenstrom Macroglobulinemia
02/28
02/28
iinnovate-1, NCT03215030: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Active, not recruiting
1/2
336
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda
Multiple Myeloma
02/24
11/24
DREAMM 5, NCT04126200 / 2019-001138-32: Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Hourglass Jul 2021 - Dec 2021 : From DREAMM-5 trial in combination with nirogacestat for r/r multiple myeloma
Hourglass Feb 2020 - Mar 2020 : Initiation of P1b sub-study of P2 DREAMM-5 trial in combination with nirogacestat for relapsed/refractory multiple myeloma
Checkmark From DREAMM 5 trial in R/R multiple myeloma patients at ASH 2019
Nov 2019 - Nov 2019: From DREAMM 5 trial in R/R multiple myeloma patients at ASH 2019
Checkmark Initiation of DREAMM-5 trial in r/r multiple myeloma
More
Recruiting
1/2
464
Europe, Canada, Japan, US, RoW
Belantamab mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab, Lenalidomide, Dexamethasone, Pomalidomide
GlaxoSmithKline
Multiple Myeloma
02/26
02/29
NCT05573802 / 2022-001942-39: A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Recruiting
1/2
36
Europe
Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone, Nirogacestat
Hellenic Society of Hematology, GlaxoSmithKline
Multiple Myeloma, Neoplasms, Neoplasm, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease
10/26
10/26
DREAMM 12, NCT04398745: A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

Recruiting
1
36
Europe, US, RoW
Belantamab mafodotin, GSK2857916
GlaxoSmithKline
Multiple Myeloma
02/25
02/25
DREAMM 13, NCT04398680: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function

Recruiting
1
28
Europe, US, RoW
Belantamab mafodotin
GlaxoSmithKline
Multiple Myeloma
11/25
11/25
ROADMAP-MM, NCT03405571: Validation of the 4TS RAM in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias.

Recruiting
N/A
800
Europe
No intervention
University of Athens, Pierre and Marie Curie University
Multiple Myeloma, Venous Thromboembolism
06/20
06/22
NCT04408209: Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection

Completed
N/A
60
Europe
Convalescent Plasma
National and Kapodistrian University of Athens, Hellenic Society of Hematology
COVID-19 Infection
08/23
12/23

Download Options